Hyep Ivan, CFO of Bicara Therapeutics Inc. ($BCAX), sold about $1.5 million in company shares across 10 open market transactions over the last 365 days, with the most recent on March 4, 2026. These sales rank 4039th among 11,678 individual insiders, below the average of $8.6 million per seller and 6 to 7 transactions. Hyep Ivan made no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 23, 2026 | Bicara Therapeutics Inc. | $BCAX | Hyep Ivan | Chief Financial Officer | M | Common Stock | 9200 | $3.79 | 154,555.0000 | 54,563,864 | 6.33% | 0.02% |
| March 23, 2026 | Bicara Therapeutics Inc. | $BCAX | Hyep Ivan | Chief Financial Officer | M | Stock Option (Right to Buy) | 9200 | $0.00 | 48,944.0000 | 54,563,864 | 15.82% | 0.02% |
| March 23, 2026 | Bicara Therapeutics Inc. | $BCAX | Hyep Ivan | Chief Financial Officer | S | Common Stock | 9200 | $18.52 | 145,355.0000 | 54,563,864 | 5.95% | 0.02% |
| March 4, 2026 | Bicara Therapeutics Inc. | $BCAX | Hyep Ivan | Chief Financial Officer | M | Stock Option (Right to Buy) | 2963 | $0.00 | 79,784.0000 | 54,563,864 | 3.58% | 0.01% |
| March 3, 2026 | Bicara Therapeutics Inc. | $BCAX | Hyep Ivan | Chief Financial Officer | M | Common Stock | 7318 | $3.79 | 152,673.0000 | 54,563,864 | 5.03% | 0.01% |
| March 3, 2026 | Bicara Therapeutics Inc. | $BCAX | Hyep Ivan | Chief Financial Officer | M | Common Stock | 6237 | $3.79 | 158,910.0000 | 54,563,864 | 4.09% | 0.01% |
| March 3, 2026 | Bicara Therapeutics Inc. | $BCAX | Hyep Ivan | Chief Financial Officer | S | Common Stock | 13555 | $18.22 | 145,355.0000 | 54,563,864 | 8.53% | 0.02% |
| March 4, 2026 | Bicara Therapeutics Inc. | $BCAX | Hyep Ivan | Chief Financial Officer | M | Common Stock | 2963 | $3.79 | 148,318.0000 | 54,563,864 | 2.04% | 0.01% |
| March 4, 2026 | Bicara Therapeutics Inc. | $BCAX | Hyep Ivan | Chief Financial Officer | S | Common Stock | 2963 | $18.25 | 145,355.0000 | 54,563,864 | 2.00% | 0.01% |
| March 3, 2026 | Bicara Therapeutics Inc. | $BCAX | Hyep Ivan | Chief Financial Officer | M | Stock Option (Right to Buy) | 7318 | $0.00 | 58,144.0000 | 54,563,864 | 11.18% | 0.01% |
| March 3, 2026 | Bicara Therapeutics Inc. | $BCAX | Hyep Ivan | Chief Financial Officer | M | Stock Option (Right to Buy) | 6237 | $0.00 | 82,747.0000 | 54,563,864 | 7.01% | 0.01% |
| Feb. 2, 2026 | Bicara Therapeutics Inc. | $BCAX | Hyep Ivan | Chief Financial Officer | A | Stock Option (Right to Buy) | 125000 | $0.00 | 125,000.0000 | 54,563,864 | 9999.99% | 0.23% |
| Jan. 22, 2026 | Bicara Therapeutics Inc. | $BCAX | Hyep Ivan | Chief Financial Officer | M | Common Stock | 1882 | $3.79 | 147,237.0000 | 54,563,864 | 1.29% | 0.00% |
| Jan. 22, 2026 | Bicara Therapeutics Inc. | $BCAX | Hyep Ivan | Chief Financial Officer | S | Common Stock | 1882 | $18.15 | 145,355.0000 | 54,563,864 | 1.28% | 0.00% |
| Jan. 22, 2026 | Bicara Therapeutics Inc. | $BCAX | Hyep Ivan | Chief Financial Officer | M | Stock Option (Right to Buy) | 1882 | $0.00 | 65,462.0000 | 54,563,864 | 2.79% | 0.00% |
| Dec. 22, 2025 | Bicara Therapeutics Inc. | $BCAX | Hyep Ivan | Chief Financial Officer | M | Stock Option (Right to Buy) | 9200 | $0.00 | 88,984.0000 | 54,563,864 | 9.37% | 0.02% |
| Dec. 22, 2025 | Bicara Therapeutics Inc. | $BCAX | Hyep Ivan | Chief Financial Officer | M | Common Stock | 9200 | $3.79 | 154,555.0000 | 54,563,864 | 6.33% | 0.02% |
| Dec. 22, 2025 | Bicara Therapeutics Inc. | $BCAX | Hyep Ivan | Chief Financial Officer | S | Common Stock | 9200 | $18.31 | 145,355.0000 | 54,563,864 | 5.95% | 0.02% |
| Nov. 24, 2025 | Bicara Therapeutics Inc. | $BCAX | Hyep Ivan | Chief Financial Officer | S | Common Stock | 17795 | $18.55 | 145,355.0000 | 54,563,864 | 10.91% | 0.03% |
| Nov. 24, 2025 | Bicara Therapeutics Inc. | $BCAX | Hyep Ivan | Chief Financial Officer | M | Common Stock | 17795 | $3.79 | 163,150.0000 | 54,563,864 | 12.24% | 0.03% |
| Nov. 21, 2025 | Bicara Therapeutics Inc. | $BCAX | Hyep Ivan | Chief Financial Officer | S | Common Stock | 605 | $18.15 | 145,355.0000 | 54,563,864 | 0.41% | 0.00% |
| Nov. 21, 2025 | Bicara Therapeutics Inc. | $BCAX | Hyep Ivan | Chief Financial Officer | M | Common Stock | 605 | $3.79 | 145,960.0000 | 54,563,864 | 0.42% | 0.00% |
| Nov. 21, 2025 | Bicara Therapeutics Inc. | $BCAX | Hyep Ivan | Chief Financial Officer | M | Stock Option (Right to Buy) | 605 | $0.00 | 115,979.0000 | 54,563,864 | 0.52% | 0.00% |
| Nov. 24, 2025 | Bicara Therapeutics Inc. | $BCAX | Hyep Ivan | Chief Financial Officer | M | Stock Option (Right to Buy) | 17795 | $0.00 | 98,184.0000 | 54,563,864 | 15.34% | 0.03% |
| Oct. 9, 2025 | Bicara Therapeutics Inc. | $BCAX | Hyep Ivan | Chief Financial Officer | S | Common Stock | 6415 | $18.23 | 145,355.0000 | 54,563,864 | 4.23% | 0.01% |
| Oct. 9, 2025 | Bicara Therapeutics Inc. | $BCAX | Hyep Ivan | Chief Financial Officer | M | Common Stock | 6415 | $3.79 | 151,770.0000 | 54,563,864 | 4.41% | 0.01% |
| Oct. 9, 2025 | Bicara Therapeutics Inc. | $BCAX | Hyep Ivan | Chief Financial Officer | M | Stock Option (Right to Buy) | 6415 | $0.00 | 116,584.0000 | 54,563,864 | 5.22% | 0.01% |
| Oct. 7, 2025 | Bicara Therapeutics Inc. | $BCAX | Hyep Ivan | Chief Financial Officer | S | Common Stock | 18244 | $18.22 | 145,355.0000 | 54,563,864 | 11.15% | 0.03% |
| Oct. 6, 2025 | Bicara Therapeutics Inc. | $BCAX | Hyep Ivan | Chief Financial Officer | M | Common Stock | 6514 | $3.79 | 151,869.0000 | 54,563,864 | 4.48% | 0.01% |
| Oct. 8, 2025 | Bicara Therapeutics Inc. | $BCAX | Hyep Ivan | Chief Financial Officer | M | Common Stock | 5627 | $3.79 | 150,982.0000 | 54,563,864 | 3.87% | 0.01% |
| Oct. 8, 2025 | Bicara Therapeutics Inc. | $BCAX | Hyep Ivan | Chief Financial Officer | S | Common Stock | 5627 | $18.21 | 145,355.0000 | 54,563,864 | 3.73% | 0.01% |
| Oct. 6, 2025 | Bicara Therapeutics Inc. | $BCAX | Hyep Ivan | Chief Financial Officer | M | Stock Option (Right to Buy) | 6514 | $0.00 | 146,870.0000 | 54,563,864 | 4.25% | 0.01% |
| Oct. 7, 2025 | Bicara Therapeutics Inc. | $BCAX | Hyep Ivan | Chief Financial Officer | M | Stock Option (Right to Buy) | 18244 | $0.00 | 128,626.0000 | 54,563,864 | 12.42% | 0.03% |
| Oct. 8, 2025 | Bicara Therapeutics Inc. | $BCAX | Hyep Ivan | Chief Financial Officer | M | Stock Option (Right to Buy) | 5627 | $0.00 | 122,999.0000 | 54,563,864 | 4.37% | 0.01% |
| Oct. 6, 2025 | Bicara Therapeutics Inc. | $BCAX | Hyep Ivan | Chief Financial Officer | S | Common Stock | 6514 | $18.17 | 145,355.0000 | 54,563,864 | 4.29% | 0.01% |
| Oct. 7, 2025 | Bicara Therapeutics Inc. | $BCAX | Hyep Ivan | Chief Financial Officer | M | Common Stock | 18244 | $3.79 | 163,599.0000 | 54,563,864 | 12.55% | 0.03% |